

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**康宁杰瑞**

ALPHAMAB ONCOLOGY

**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the announcement dated April 14, 2020 (the “**Announcement**”) of Alphamab Oncology (the “**Company**”) in relation to the adoption of the Post-IPO Share Option Scheme, which was adopted by the Company on May 25, 2020. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) announces that on October 24, 2022 (the “**Date of Grant**”), pursuant to the Post-IPO Share Option Scheme, the Company resolved to grant share options (the “**Options**”) to eligible participants (the “**Grantees**”), who are employees of the Company and its subsidiaries, to subscribe for up to an aggregate of 220,000 ordinary shares of the Company of US\$0.000002 each (the “**Shares**”) in the capital of the Company, subject to the acceptance of the Grantees.

Details of the Options granted are as follows:

<b>Date of Grant</b>	October 24, 2022
<b>Exercise price of the Options granted</b>	HK\$6.214 per Share, representing the highest of (i) the closing price of HK\$5.690 per Share as stated in the daily quotations sheet issued by the Stock Exchange on the Date of Grant; (ii) the average closing price of HK\$6.214 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share of US\$0.000002
<b>Total number of Options granted</b>	220,000 Options (each Option shall entitle the holder of the Option to subscribe for one Share)
<b>Validity period of the grant of the Options</b>	Ten (10) years from the Date of Grant

**Vesting schedule of  
the Options**

44,000 Options shall be vested on October 24, 2023;

44,000 Options shall be vested on October 24, 2024;

44,000 Options shall be vested on October 24, 2025; and

88,000 Options shall be vested on October 24, 2026.

**Grantees**

None of the Grantees is a Director, chief executive or substantial shareholder of the Company, nor a connected person or an associate (as defined under the Rule 14A.06 of the Listing Rules) of any of them.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, October 24, 2022

*As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin as Non-executive Director and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.*